StockpollyBeta
Get App

Categories·Biotech

New Drug Development

Companies that use cell culture and genetic recombination to develop groundbreaking new drugs and export the underlying technology.

+1.25% today·581 stocks·3 sub-categories

Stocks

By market cap · 581 stocks

  1. 1ABBVAbbVieImmunology drugmaker behind Skyrizi, Rinvoq, and Botox$467.37B+0.57%
  2. 2MRKMerckMaker of Keytruda, vaccines, and animal medicines$369.24B+1.79%
  3. 3AZNAstraZeneca (ADR)Oncology-led developer of specialty medicines$260.70B+0.15%
  4. 4AMGNAmgenMaker of Prolia, Repatha, and rare-disease medicines$212.19B+3.63%
  5. 5GILDGilead SciencesDeveloper of HIV, liver-disease, and cancer medicines$186.93B+1.12%
  6. 6BMYBristol-Myers SquibbDeveloper of Eliquis, Opdivo and specialty medicines$127.91B+0.13%
  7. 7REGNRegeneronMaker of Dupixent, EYLEA HD, and Libtayo$82.23B+0.80%
  8. 8MRNAModernaDeveloper of mRNA vaccines and therapeutics$68.62B+3.97%
  9. 9ARGXargenx (ADR)Developer of VYVGART autoimmune medicines$61.45B−1.21%
  10. 10RVMDRevolution MedicinesDeveloper of RAS(ON) oncology candidates$40.98B+0.68%
  11. 11ONCBeOne Medicines (ADR)Developer of BRUKINSA and TEVIMBRA oncology medicines$39.07B−0.59%
  12. 12ALNYAlnylam PharmaceuticalsRNAi medicines built around gene-silencing delivery$32.69B+3.87%
  13. 13BIIBBiogenNeuroscience medicines across MS and rare disease$32.37B+2.73%
  14. 14ROIVRoivant SciencesVant-based developer of immunology medicines$28.17B−0.96%
  15. 15INSMInsmedTwo marketed pulmonary medicines and gene therapies$26.23B−0.98%
  16. 16RPRXRoyalty PharmaBuyer and funder of drug royalties$25.90B+0.36%
  17. 17INCYIncyteJakafi-led hematology, oncology, and immunology drug developer$25.27B+1.60%
  18. 18BNTXBioNTech (ADR)Comirnaty developer with an oncology pipeline$24.62B+2.56%
  19. 19GMABGenmab (ADR)Builder of antibody medicines and bispecific platforms$21.30B+0.71%
  20. 20UTHRUnited TherapeuticsMaker of Tyvaso and investigational organ alternatives$20.93B+0.37%
  21. 21JAZZJazz PharmaceuticalsSleep, epilepsy and oncology rare-disease medicines$15.17B−0.27%
  22. 22NBIXNeurocrine BiosciencesDeveloper of INGREZZA and rare-disease medicines$14.48B−0.24%
  23. 23EXELExelixisBuilder of the cabozantinib oncology franchise$14.38B+2.41%
  24. 24SMMTSummit TherapeuticsDeveloper of ivonescimab for solid tumors$13.48B+1.55%
  25. 25HALOHalozyme TherapeuticsENHANZE platform for subcutaneous drug delivery$13.22B+2.03%
  26. 26BBIOBridgeBio PharmaAttruby-led genetic disease drug developer$13.04B+3.88%
  27. 27BMRNBioMarinRare-disease therapies spanning enzymes and skeletal conditions$12.38B+0.89%
  28. 28MDGLMadrigal PharmaceuticalsMASH drug developer behind Rezdiffra$12.06B−0.02%
  29. 29BAXBaxter InternationalHospital infusion, connected-care, and injectable products$11.85B+3.69%
  30. 30AXSMAxsome TherapeuticsCNS medicines for depression, agitation, sleepiness, and migraine$10.57B−0.20%
  31. 31KRYSKrystal BiotechTopical VYJUVEK and redosable genetic medicine pipeline$9.84B+4.72%
  32. 32ARWRArrowhead PharmaceuticalsDeveloper of targeted RNAi medicines$9.69B+3.96%
  33. 33KYMRKymera TherapeuticsOral protein degraders for immunological diseases$9.68B+2.64%
  34. 34PTGXProtagonist TherapeuticsPeptide-drug developer behind ICOTYDE and rusfertide$9.32B+0.59%
  35. 35IBRXImmunityBioMaker of ANKTIVA and cellular immunotherapies$8.85B+5.07%
  36. 36TGTXTG TherapeuticsCommercializer of BRIUMVI for relapsing multiple sclerosis$8.75B−0.19%
  37. 37PCVXVaxcyteDeveloper of high-valency pneumococcal vaccines$8.51B+0.41%
  38. 38CYTKCytokineticsDeveloper of MYQORZO and cardiac muscle medicines$8.41B+1.47%
  39. 39PRAXPraxis Precision MedicinesPrecision neuroscience drug developer for tremor and epilepsy$8.33B+1.75%
  40. 40SYRESpyre TherapeuticsDeveloper of long-acting immunology antibody combinations$7.99B−0.81%
  41. 41IMVTImmunovantDeveloper of imeroprubart for autoimmune diseases$7.67B+0.22%
  42. 42ABVXAbivax (ADR)Developer of oral obefazimod for inflammation$7.60B−4.66%
  43. 43IONSIonis PharmaceuticalsAntisense medicines with owned and partnered launches$7.46B+0.65%
  44. 44BLTEBelite Bio (ADR)Developer of oral retinal-disease therapies$6.95B+1.49%
  45. 45CGONCG OncologyCretostimogene developer and contract manufacturer$6.90B−1.44%
  46. 46RYTMRhythm PharmaceuticalsMC4R therapies for rare neuroendocrine obesity$6.78B+1.50%
  47. 47GRFSGrifols (ADR)Integrated plasma therapies and diagnostics$6.23B+0.68%
  48. 48KNSAKiniksa PharmaceuticalsARCALYST marketer for recurrent pericarditis$5.95B+0.38%
  49. 49TVTXTravere TherapeuticsRare kidney-disease medicines led by FILSPARI$5.85B−3.41%
  50. 50LGNDLigand PharmaceuticalsBiopharmaceutical royalty aggregator with Captisol and NITRICIL$5.81B+0.88%